Davita Inc vs Marqeta Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Marqeta Inc trades at $17.36 (market cap $1.82B). The key difference: Davita Inc is far larger — about 6.2× Marqeta Inc's market cap, and Davita Inc is more actively traded (582,204 versus 1,126,466). Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Marqeta Inc for 44 Days on average.
| DVA | MQ | |
|---|---|---|
Market Cap | $11.29B | $1.82B |
Volume | 582,204 | 1,126,466 |
Sector | Health | Technology |
52-Week High | $240.96 | $20.32 |
52-Week Low | $103.87 | $15.04 |
Typical Hold Time | 113 Days | 44 Days |
Enterprise Value | $24.01B | $1.13B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Marqeta (MQ) trades at $17.06, up 3.08% with a bullish technical signal from moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and revenue growth from $507M in 2024 to projected $677M in 2026. Recent partnerships with BVNK for stablecoin cards and Google for wallet expansion highlight strategic growth initiatives. However, valuation metrics remain elevated with a P/E of 189.56 and EV/EBITDA of 52.44 despite modest profitability margins.
MQ presents a mixed outlook with strong operational momentum but premium valuation. The stock offers growth potential through expanding payment partnerships and enterprise adoption, though faces risks from contract renewals in Q3 2026 and competitive pressure. Analyst consensus of $11.38 suggests caution despite recent bullish earnings revisions and institutional interest in the digital payments space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →